{"id":957136,"date":"2026-05-13T13:41:15","date_gmt":"2026-05-13T13:41:15","guid":{"rendered":"https:\/\/www.europesays.com\/uk\/957136\/"},"modified":"2026-05-13T13:41:15","modified_gmt":"2026-05-13T13:41:15","slug":"health-panel-approves-coverage-for-ips-cell-derived-parkinsons-disease-treatment","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/uk\/957136\/","title":{"rendered":"Health panel approves coverage for iPS cell-derived Parkinson\u2019s disease treatment"},"content":{"rendered":"<p>An advisory panel to the health minister on Wednesday approved Sumitomo Pharma\u2019s Parkinson\u2019s disease treatment Amchepry, which costs \u00a555.3 million ($350,600) per patient, to be covered under the national healthcare program.<\/p>\n<p>The approval marks the first commercialized medical product in the world derived from iPS cells, which are created by reprogramming adult cells such as blood or skin cells into a versatile state capable of developing into different tissue types.<\/p>\n<p>Insurance coverage will begin May 20, with treatment expected to be available this fall, according to media reports.<\/p>\n","protected":false},"excerpt":{"rendered":"An advisory panel to the health minister on Wednesday approved Sumitomo Pharma\u2019s Parkinson\u2019s disease treatment Amchepry, which costs&hellip;\n","protected":false},"author":2,"featured_media":957137,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4316],"tags":[535,105,4348,3912,85745,34696,16,15],"class_list":{"0":"post-957136","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-healthcare","8":"tag-drugs","9":"tag-health","10":"tag-healthcare","11":"tag-medicine","12":"tag-mhlw","13":"tag-parkinson","14":"tag-uk","15":"tag-united-kingdom"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@uk\/116567558609709057","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/957136","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/comments?post=957136"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/957136\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media\/957137"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media?parent=957136"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/categories?post=957136"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/tags?post=957136"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}